Ipilimumab,
does it really help with Prevention of recurrence, distant metastasis, and death after complete resection of high-risk stage III melanoma as adjuvant therapy?
research showsAdjuvant ipilimumab monotherapy is rated B because EORTC 18071 reduced recurrence, distant metastasis, and death versus placebo. Five-year overall survival was 65.4% versus 54.4%, with a hazard ratio for death of 0.72. However, grade 3 or 4 immune-related events occurred in 41.6%, treatment-related deaths occurred in 1.1%, and CheckMate 238 showed better recurrence-free survival and tolerability with the anti-PD-1 agent nivolumab.
ads claimClaims that immunotherapy completely prevents postoperative recurrence are exaggerated. Recurrence still occurs, and ipilimumab carries particularly substantial immune toxicity.
Useful facts when choosing a product
- Ipilimumab is an intravenous CTLA-4 checkpoint inhibitor; the evidence here concerns monotherapy after complete resection of high-risk stage III melanoma.
- EORTC 18071 used 10 mg/kg for four induction doses followed by maintenance for up to three years, while anti-PD-1 therapy is now generally preferred in the adjuvant setting.
- Immune-mediated colitis, hepatitis, skin reactions, hypophysitis, thyroid or adrenal disorders, and rare fatal immune events require rapid recognition and immunosuppressive management.
What the research actually shows
EORTC 18071 randomized 951 patients with completely resected stage III melanoma to ipilimumab or placebo. Five-year recurrence-free survival was 40.8% versus 30.3%, distant-metastasis-free survival was 48.3% versus 38.9%, and overall survival was 65.4% versus 54.4%. In 906 CheckMate 238 patients, 12-month recurrence-free survival was 70.5% with nivolumab versus 60.8% with ipilimumab, while treatment-related grade 3 or 4 events were 14.4% versus 45.9%.
Why this is classified as B (77)
The placebo-controlled overall-survival benefit is strong, but severe or fatal toxicity and direct inferiority to anti-PD-1 therapy yield B with 77 points.
Counterpoint. Unless anti-PD-1 therapy is unsuitable or inaccessible, adjuvant selection should compare recurrence risk, toxicity, BRAF status, and available alternatives.
Rejudgment record. Cross-check applied — Accepted the agent-specific placebo-controlled overall-survival benefit in EORTC 18071 while applying a substitution ceiling for severe or fatal immune toxicity and direct inferiority to anti-PD-1 therapy in CheckMate 238. At cross-check the score was set to the top of B (77) to reflect the overall-survival hard-endpoint benefit in EORTC-18071 (grade B retained).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved recurrence-free survival | B | Five-year rates were 40.8% versus 30.3%, with a hazard ratio of 0.76. |
| Prevention of distant metastasis | B | Five-year distant-metastasis-free survival was 48.3% versus 38.9%. |
| Improved overall survival | B | Five-year overall survival was 65.4% versus 54.4%, with a hazard ratio for death of 0.72. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Eggermont AMM et al. EORTC 18071. 2016 | Multicenter double-blind placebo-controlled phase 3 randomized trial | 951 | Bristol-Myers Squibb | Recurrence-free, distant-metastasis-free, and overall survival | Five-year overall survival was 65.4% versus 54.4%; hazard ratio for death 0.72. | Key placebo-controlled hard endpoint |
| Weber J et al. CheckMate 238. 2017 | Phase 3 randomized trial of nivolumab versus ipilimumab | 906 | Bristol-Myers Squibb and Ono | Recurrence-free survival and safety | Nivolumab was superior for recurrence-free survival; grade 3 or 4 events were 14.4% versus 45.9%. | Direct modern-substitute comparison |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Ipilimumab x prevention of recurrence, distant metastasis, and death after complete resection of high-risk stage iii melanoma as adjuvant therapy — Evidence Grade B·77. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/ipilimumab-adjuvant-stage-iii-melanoma-survival/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.